Sansum Diabetes Research Institute
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Sansum Diabetes Research Institute sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).
Sansum Diabetes Research Institute: 33 sponsored US clinical trials, none currently recruiting.
Sansum Diabetes Research Institute sponsors 33 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 29 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 3 trials.
Top-decile sponsor footprint
Sansum Diabetes Research Institute ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
29 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
33 total, page 1 of 1
Integrating Abbott Point-of-Care Technologies and the Community Scientist Model to Support HbA1c Testing Per ADA
NCT05000840
Community-Based Nutrition-Lifestyle Therapy for Pregnant Latina Women With Diabetes
NCT06218147
Acceptability & Impact of a Diabetes Management Smartphone App (mySugr) for Spanish-literate Adults With Type 2 Diabetes
NCT05975242
Continuous Glucose Monitoring and Hass Avocado Trial ("CHAT")
NCT05293340
Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care
NCT04938388
Assessing Adherence to Digital Health Technologies Among Hispanic/Latino Adults With or At Risk of Type 2 Diabetes:
NCT04820348
The International Diabetes Closed Loop (iDCL) Trial: Protocol 4
NCT04436796
Automated Insulin Delivery in Pregnant Patients With Type 1 Diabetes With Extension Into Outpatient at Home
NCT04492566
Artificial Pancreas With Different Stress Assessments in the Outpatient Setting
NCT04142229
Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy
NCT04016584
Mil Familias Cohort Establishment: a Study to Understand Determinants of Diabetes and Its Complications Among US Latinos
NCT03830840
Farming for Life - Health Impact of Organic Vegetable Prescriptions for Adults Living With or at Risk of Type 2 Diabetes
NCT03940300
Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) With Different Food Choices in the Outpatient Setting
NCT03767790
Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
NCT03668808
Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy
NCT03761615
Safety and Feasibility Evaluation of the APS APP
NCT03504046
A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)
NCT03362151
Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes
NCT03307850
Mil Familias-Santa Barbara's Operational Pilot to Understand Diabetes in the Latino Community
NCT03736486
Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index
NCT03092310
At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation
NCT02705053
Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting
NCT02463682
MPC Versus PID for Closed Loop Insulin Delivery
NCT02438670
Feasibility Study Using Run-to-Run Control to Optimize Continuous Glucose Sensor Bias
NCT02290600
Feasibility Study of PID Versus MPC and HMS
NCT01987206
Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control
NCT02190669
Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin
NCT01929798
Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
NCT01662921
Performance Evaluation of a Non-Invasive Glucose Monitor as Compared to CGM Data Acquired by the iPro2
NCT01831752
Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp
NCT01874392
Outpatient Control-to-Range: System and Monitoring Testing
NCT01697150
Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)
NCT01472406
Controlled Insulin Delivery: Combining Technology With Treatment
NCT01484457
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
How the Sansum Diabetes Research Institute early-phase archive is shaped
33 indexed studies, none listed as recruiting (0% open); 29 completed (88%).
Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Type 1 Diabetes Mellitus (3 trials), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Sansum Diabetes Research Institute: archived-pipeline peers nationwide
Peers matched on 33 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Sansum Diabetes Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 33 archived trials
- Aclaris Therapeutics · 33 trials · 3% recruiting
- Antonios Likourezos · 33 trials · 12% recruiting
- Baylor University · 33 trials · 15% recruiting
- Becton, Dickinson and Company · 33 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Sansum Diabetes Research Institute page
33 registered trials is a research-attention snapshot, not an endorsement of Sansum Diabetes Research Institute or any single study.
- None of Sansum Diabetes Research Institute's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Type 1 Diabetes Mellitus is the condition Sansum Diabetes Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sansum Diabetes Research Institute pipeline card: 33 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.